Little Cara steers through their first positive PhIII with a ‘breakthrough’ drug and a path to the FDA

Cara Therapeutics $CARA has successfully hit a key milestone in its push to get their lead drug across the finish line at the FDA. The biotech says it racked up a set of clearly positive data for their one drug, Korsuva (CR845), in their first Phase III trial readout for a severe itching condition among patients on hemodialysis.